How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?

Abstract

Cancer, also known as malignant tumour or neoplasm, is a leading cause of death worldwide. One distinct feature from normal cells is that cancerous cells often overexpress protein on the cell membrane—for instance, the overexpression of human epidermal growth factor receptor 2. The expression of a specific protein on the cancerous cell surface acts as a marker that differentiates the normal cell and facilitates the recognition of cancerous cells. An emerging anticancer treatment, Antibody–Drug Conjugates (ADCs), utilises this unique feature to kill cancerous cells. ADCs consist of an antibody linked with a cytotoxic payload, mainly targeting the antigen found on cancerous cells. This design can increase the specificity in delivering the cytotoxin to the drug target, thus increasing the drug efficacy and reducing the side effect of cancer treatment due to off-target toxicities. There are tremendous quantities of clinical trials conducted to evaluate the safety and effectiveness of this magic drug in treating different types of cancers. However, only 12 ADCs have been approved by the FDA until now. This review provides the principles of ADCs and highlights the ADCs that FDA has approved. In addition, some of the ADCs that undergo clinical trials are discussed in this review. The application of computational techniques in addressing ADCs’ challenges and neoantigen-targeted cancer vaccines is also highlighted. Although ADCs have been seen as promising magic drugs in cancer treatment, the problems such as toxicity, the stability of the linker, the specificity of an antibody with antigen, and so on, remain a challenge in developing ADCs.

Perspective of Fibrin Capsule in Inhibition of Growth and Metastasis of Malignant Tumors

“…similar to the attachment of the MCC-DM1 molecule to the Trastuzumab-emtansine structure [37,38]. The peptide bound is formed between the free amino group of trastuzumab and the carboxyl group of the fibrinogen molecule.…”

“…Пропонуємо здійснити приєднання молекули фібриногену до трастузумабу через утворення пептидного зв'язку аналогічно до приєднання молекули МСС-DM1 у структуру Трастузумаб-емтанзину [37,38]. Пептидний зв'язок утвориться між вільною аміногрупою трастузумабу й карбоксильною групою молекули фібриногену.…”